Many patients with peripheral nerve diseases do not have a sufficient regenerative response because of genetic inheritance, infections or chronic disease, leading them to lifelong pain and disability.

Adolore Biotherapeutics Inc. has offered an update on recent pipeline development progress as it advances nonopioid analgesic gene therapies for the treatment of chronic pain.

Correcting the deficiency of potassium intake in astrocytes could improve the symptoms of fragile X syndrome (FXS).

Kate Therapeutics Inc. recently presented data on a novel muscle- and heart-targeted, liver de-targeted development candidate for the treatment of Duchenne muscular dystrophy (DMD) – KT-809.

A group of scientists from Harvard University have observed and reconstructed the human brain at the resolution of the electron microscope, with all its cells, following all the connections between its neurons around a cubic millimeter of a tissue sample. They took 10 years and the data occupies 1.4 petabytes (1,400 terabytes). However, they are already planning a bigger project.

Alto Neuroscience Inc.’s start this spring of the phase II double-blind, single- and multiple-dose study to test the pharmacodynamics of ALTO-203 in major depressive disorder represents another stake planted in a notoriously difficult indication. But getting attention as well is the push by Los Altos, Calif.-based Alto in post-traumatic stress disorder (PTSD) with a separate compound.